PMV Pharmaceuticals

PMVP · NASDAQ

$1.39+$0.135 (+10.76%)TodayMarket closed · Oct 20, 7:33 PM ET

Prev close $1.26

PMVP analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $4.28 (+208.2% upside)

Low: $3.03
Now: $1.39
High: $5.25

Upgrades and downgrades

The latest rating actions, newest first

PMVP analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Sep 4, 2026	Maintains	Buy	$5.00	41%
Ladenburg Thalmann	Jul 8, 2026	Initiates	Buy	$3.00	—
Oppenheimer	May 13, 2026	Maintains	Outperform	$6.00 → $5.00	33%

The case for and against

Updated Nov 30, 2024

Bull case

PMV Pharmaceuticals Inc. has successfully aligned with the FDA on critical aspects of the Phase 2 registrational portion of the PYNNACLE trial, which enhances the potential for regulatory approval of its lead candidate, PC14586, particularly in combination with Keytruda for treating advanced solid tumors with p53 Y220C mutations. The ongoing enrollment in this trial, along with the encouraging response rates observed across various cancer types—including ovarian, breast, small-cell lung, and endometrial cancers—indicates a favorable outlook for the efficacy of these therapies. Additionally, the company's relatively benign safety profile allows for the possibility of effective combinations with other agents, potentially broadening treatment options and improving outcomes for patients.

Bear case

The financial outlook for PMV Pharmaceuticals Inc. reflects significant risks that contribute to a negative assessment of the company's stock. Key concerns include the potential for negative clinical data related to the PC14586 therapy, delays in advancing candidates to later-stage trials, and the high likelihood of substantial net losses, with a projected full-year 2024 net loss of $1.53 per share. Additionally, there are ongoing uncertainties regarding regulatory approvals and commercial success, coupled with risks of dilution that could impede the company's financial stability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.